Researchers of the Paul-Ehrlich-Institut have developed a humanised mouse model that can be used to predict severe adverse immune reactions after administration of the monoclonal antibody TGN1412. A few years ago, the antibody led to severe immune reactions as a result of a cytokine storm in a clinical trial with healthy volunteers. The humanised mouse model can contribute to increasing the safety in first-in-man use of certain antibodies. PLOS ONE reports on the research results in his online version of March 9, 2016.
TGN1412 – the effects of the clinical trial with this humanised "superagonistic" monoclonal antibody can still be felt today. TGN1412 was developed for the treatment of rheumatoid arthritis and a particular form of leukaemia.
In 2006, the antibody was administrated in a first-in-man study to six healthy volunteers in the UK. All volunteers developed massive release of immunological messenger substances (cytokine storm) with life-threatening symptoms only a short time after they received TGN1412.
In the preliminary animal experiments – an important component of the required studies before first use in humans – no risks became apparent. The severe immunological reactions thus came as a surprise.
For this reason, since this event, researchers have been seeking methods of studying and estimating such severe adverse effects as a result of immunological reactions before first use in humans. Immunologists of the Paul-Ehrlich-Institut (PEI) who are supervised by and collaborating with Priv.-Doz. (associate professor) Dr Zoe Waibler, head of a temporary research group, investigated whether a humanised mouse model could be suitable for this.
They used so-called knock-out mice, in which specific genes of the immune system of the mouse are deactivated. These mice are substituted with cells of the immune system from human blood.
In addition to TGN1412, the scientists also used the monoclonal antibody OKT3, of which it is also known that it can cause severe cytokine storms. The scientists were able to detect cytokine release in the blood samples of the animals for both antibodies. Thus, for instance interferon-gamma levels increased considerably after the administration of the antibody.
Besides, the scientists observed additional effects equivalent to those observed in humans. These included the loss of leucocytes (white blood cells) after the administration of TGN1412 and the typical loss of particular surface markers (CD3) on T cells typically observed after the administration of OKT3. These cells play an important part in the human immune system.
However, what was a lot more obvious related to the clinical symptoms: The body temperature of the animals decreased. This is a sure sign of disease in mice comparable to high temperatures in humans. The general state of health of the mice, too, deteriorated significantly in only few hours. "Based on the symptoms and the blood samples in this mouse model, we can see adverse effects at an early stage without having to know in detail in advance what exactly we are looking for. This is a significant use of the mouse model", as Ms Waibler explained the results.
This animal model, above all, makes immunological effects visible which are mediated via T cells of the immune system. Even though the animal model involves a high workload, it opens up options of approaches to improving safety before first use in humans during clinical trials of monoclonal antibodies, for which a T-cell-mediated reaction could be expected and for which a severe immune reaction must be ruled out.
Weißmüller S, Bauer S, Kreuz D, Schnierle B, Kalinke U, Kirberg J, Hanschmann KM, Waibler Z (2016): TGN1412 induces lymphopenia and human cytokine release in a humanized mouse model.
PLOS ONEMar 9 [Epub ahead of print].
http://dx.plos.org/10.1371/journal.pone.0149093 - Online-Version of the Publication
http://www.pei.de/EN/information/journalists-press/press-releases/2016/07-mouse-... This press release on the PEI-Website
Dr. Susanne Stöcker | Paul-Ehrlich-Institut - Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel
Seeing on the Quick: New Insights into Active Vision in the Brain
15.08.2018 | Eberhard Karls Universität Tübingen
New Approach to Treating Chronic Itch
15.08.2018 | Universität Zürich
Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...
Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.
When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.
Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...
Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur
What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...
08.08.2018 | Event News
27.07.2018 | Event News
25.07.2018 | Event News
15.08.2018 | Physics and Astronomy
15.08.2018 | Earth Sciences
15.08.2018 | Physics and Astronomy